OBJECTIVES: A published economic model of biological therapies for moderate to severe Crohn’s disease was used recently in the National Institute for Health and Care Excellence (NICE) technology appraisal for vedolizumab. The objective of this study was to identify key drivers of cost effectiveness in Crohn’s disease. METHODS: The published economic model was reconstructed using data from Bodger et alRESULTS: For the base case results, Bodger et al